ViroGates Logo

ViroGates has announced the issue of new shares with pre-emptive rights for existing shareholders.

ViroGates has developed positively with solid revenue growth and a doubling of routine customers in recent quarters. COVID-19 has challenged our existing business in the emergency departments in Europe. Due to the unpredictability of the pandemic and the potential impact on the business, we want to ensure that we have sufficient capital to realize the company’s full potential in the long run. In addition, we have identified two initiatives with great potential to increase growth.

ViroGates needs additional capital to invest in two growth initiatives:

1) Obtain reimbursement for the use of suPARnostic® in various markets in Europe

We plan to prepare and submit reimbursement applications in up to eight European markets within COVID-19 and, subsequently, the emergency department. Our strong COVID-19 data can be an effective way to obtain reimbursement, facilitating increased use of suPARnostic®.

2) Begin expansion to the US

We want to start the work of entering the USA with our products. Initially, we will focus on COVID-19 through an “emergency use authorization”. This work will also benefit the company in the longer term to prepare and submit a so-called 510K application for use in emergency departments. In the longer term, we intend to roll out sales via a licensing partner in the US.

Download our investment brochure

ViroGates is on a positive trajectory with a strong revenue and customer growth in recent quarters. However, the COVID-19 pandemic has challenged the core business. Given the uncertain course of the pandemic and its potential negative commercial impact on the company, ViroGates needs to ensure sufficient runway to realize the full potential in the acute care segment. In addition, ViroGates has identified two initiatives with significant potential that can further boost growth. ViroGates needs additional financing to invest in the two growth initiatives and realize the significant expected spillover effects to existing activities.

Doctor in the facemask

Watch the suPARnostic® video to learn more about suPAR

Offering and timeline

ViroGates is offering new shares for a maximum of DKK 19 million for the two initiatives and the existing business. In addition to the rights issue, we are in dialogue with Danish lenders about a loan financing of DKK 9-12.5 million.

timeline for the rights issue

You can exercise your subscription rights through your custodian (bank) and read more about the share issue in the investment brochure below.

We hope for your support in bringing the initiatives to life and creating a better and more efficient health system for the benefit of all.

Historical financial reports

Annual Report 2021

2021 was an exciting year for ViroGates. The company delivered revenue growth of 43% and achieved extraordinary scientific results. However, the global COVID-19 continued to affect the business negatively with many hospitals unable to onboard new technologies during a state of emergency. Despite the challenges, ViroGates welcomed several new customers across markets and managed to shift sales further towards clinically relevant products.

Click here to download ViroGates’ Annual Report 2021.

Investor meetings in connection with the Offering

ViroGates have hosted two virtual investor meetings in connection with the offering:

Thursday, 23 June 2022, 14.00 CET: Västra Hamnen Corporate Finance (English).

Friday, 24 June 2022, 10.00 CET: HC Andersen Capital (Danish).                           .

Jakob Knudsen, CEO

“We will use the experiences of the first years as a commercial company to further boost growth.”

– Jakob Knudsen, Chief Executive Officer, ViroGates

IR contact

Jakob Knudsen
Tel. +45 2113 1336

Certified Advisor

Västra Hamnen Corporate Finance
Per Lönn
Tel. +46 40 200 250


published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 3 products:

Quick Triage

A Point of Care Solution


For Automated Systems


Clinical and Research

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates